Healthcare Market Research Reports Analysis and Trends

Publication Single User License (PDF) Price
Argentina Pharmaceuticals and Healthcare Report Q1 2015

Argentina Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 26 2014

BMI View: We expect increasing competitive pressure in the Argentine pharmaceutical sector as South-
South relations continue to develop. This is illustrated by the Argentine government recent authorization for
Indian pharmaceutical firms to export finished formulations to Argentina. Argentina's debt default poses
downside risk to economic activity in the next quarters, while we expect inflation and drug pricing controls
to continue hampering the pharmaceutical market potential. The challenging business environment in the

$1,295.00
Botswana Pharmaceuticals and Healthcare Report Q1 2015

Botswana Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 26 2014

BMI View: Our outlook for the pharmaceutical and healthcare markets of Botswana is reasonably positive
due to the government's increasing commitment to improve the country's healthcare sector. The country's
import reliance for pharmaceuticals, coupled with the forecast depreciation of the Botswana pula will be
seen as a negative for the local industry as imports will become increasingly expensive.
Headline Expenditure Projections
■ Pharmaceuticals: BWP1.66bn (USD198mn) in 2013 to BWP1.85bn (USD207mn) in 2014; +11.3% in

$1,295.00
Cameroon Pharmaceuticals and Healthcare Report Q1 2015

Cameroon Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 26 2014

BMI View: Against a backdrop of sustained economic growth, Cameroon's pharmaceuticals and healthcare
market will sustain an expansive trajectory over the medium-to-long term. Although from a low per-capita
spending level, population growth and rising incomes will drive drug consumption in the foreseeable future.
A number of public and private investment projects across the healthcare system will contribute to overall
sector growth, as illustrated by recent investment projects by Swiss entrepreneurs, and continued global aid

$1,295.00
Mozambique Pharmaceuticals and Healthcare Report Q1 2015

Mozambique Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 26 2014

BMI View: Mozambique has a fast-growing economy thanks to its natural resources and agricultural
industry. The Mozambican government continues to show its commitment towards the development of
healthcare infrastructure by tackling the country's shortages of health professionals and clinic with the aid
of foreign investors. However, barriers to investment remain, including high levels of corruption and lowlevel
political instability, working against market growth.
Headline Expenditure Forecasts

$1,295.00
Singapore Pharmaceuticals and Healthcare Report Q1 2015

Singapore Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 26 2014

BMI View: Driven by a rapidly ageing population and growing government health expenditure,
Singapore's pharmaceutical sales will continue its steady growth over the next decade. This growth is only
constrained by its small population. The country's high levels of education, strong patent protection and
good infrastructure also makes it a highly competitive location for international pharmaceutical companies
to establish research and development and manufacturing facilities as the region integrates closer with the
ASEAN Economic Community.

$1,295.00
Japan Pharmaceuticals and Healthcare Report Q1 2015

Japan Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 19 2014

BMI View: The Japanese pharmaceutical market continues to hold strong rewards for innovative
pharmaceutical companies. This is driven by the country's rapidly ageing population, preference for branded
medicines and strong public coverage of drug expenditure. However, the cost containment measures by the
government including aggressively cutting medicine prices pose a downward risk to the market's long term
growth.
Risk/Reward Index
Japan's Pharmaceutical Risk/Reward Index (RRI) score for Q115 increased to 78.1 out of the maximum 100

$1,295.00
Jordan Pharmaceuticals and Healthcare Report Q1 2015

Jordan Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 19 2014

BMI View: Continuing political instability in the region is having a detrimental impact on the country's
economy and healthcare sector which is burdened with many Syrian refugees. The Jordanian government is
continuing to invest in the country's healthcare sector through training more staff and developing
additional infrastructure. This will expand access to health services among the population and provide
opportunities for drugmakers looking to enter the Jordanian pharmaceutical market.
Headline Expenditure Projections

$1,295.00
Latvia Pharmaceuticals and Healthcare Report Q1 2015

Latvia Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 19 2014

BMI View: Market growth forecasts are strong although the country will continue to present a modest
opportunity to larger multinational companies on account of its relatively small market size. Meanwhile,
tensions between Ukraine and Russia may provide challenges for local manufacturers that had sought
exports to Russia and the Commonwealth of Independent States (CIS) region as a remedy for lacklustre
domestic demand in recent years.
Headline Expenditure Projections

$1,295.00
Romania Pharmaceuticals and Healthcare Report Q1 2015

Romania Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 19 2014

BMI View: Romania's claw back tax is likely to see a revision as domestic companies lobby to push the
burden further onto innovative drugmakers. With an improving macroeconomic outlook, increased
government spending is on the horizon, and that will undoubtedly benefit the pharmaceutical sector.
However, stalling Eurozone growth could worsen dynamics within Romania.
Headline Expenditure Projections
■ Pharmaceuticals: RON13.96bn (USD4.17bn) in 2013 to RON14.65bn (USD4.38bn) in 2014; +5.0% in
local currency terms and 5.0% in US dollar terms.

$1,295.00
Tanzania Pharmaceuticals and Healthcare Report Q1 2015

Tanzania Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 19 2014

BMI View: We expect the continuing depreciation of the Tanzanian shilling to make imports of raw
materials increasingly expensive for the few remaining domestic pharmaceutical manufacturers. A tax
regime that favours imports of finished pharmaceuticals and a lack of skilled labour will be detrimental to
local manufacturers, and will see the country remain reliant on imported pharmaceuticals for the
foreseeable future.
Headline Expenditure Projections
■ Pharmaceuticals: TZS693.86bn (USD429mn) in 2013 to an expected TZS794.60bn (USD488mn) in

$1,295.00
Algeria Pharmaceuticals and Healthcare Report Q1 2015

Algeria Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 19 2014

BMI View: Against a backdrop of economic growth, the Algerian government commitment to expand and
upgrade medical coverage and healthcare services in Algeria will translate in growing commercial
opportunities for pharmaceutical and healthcare industries over the medium term. Also, the government's
new five-year investment plan to be implemented in 2015-2019 will focus on diversifying the economy
through the promotion of industrial development, including the pharmaceutical industry. In line with such

$1,295.00
Angola Pharmaceuticals and Healthcare Report Q1 2015

Angola Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 19 2014

BMI View: The Angolan government's initiatives to make healthcare more affordable, coupled with the
municipalisation of health services, will lead to greater access to medical services and increase
pharmaceutical spending in Angola. A new medicine depot is a step in the right direction towards
improving the traditionally difficult operating environment of the country's pharmaceutical and healthcare
markets. However, poor patent protection, a lack of hospitals and clinics, and the threat of counterfeit

$1,295.00
Bulgaria Pharmaceuticals and Healthcare Report Q1 2015

Bulgaria Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 19 2014

BMI View: Large order increases from within the hospital sector and robust consumer demand will spur
pharmaceutical sales growth in 2014 and 2015. However, external slowdown will begin to impact the
Bulgarian market from 2015 onwards. Bulgaria's healthcare system will continue to face issues around its
funding.
Headline Expenditure Projections
■ Pharmaceuticals: BGN2.32bn (USD1.58bn) in 2013 to BGN2.44bn (USD1.67bn) in 2014; +5.0% in
local currency terms and 5.7% in US dollar terms. US dollar forecast revised upward due to expectations

$1,295.00
Cote d'Ivoire Pharmaceuticals and Healthcare Report Q1 2015

Cote d'Ivoire Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 19 2014

BMI View: Côte d'Ivoire's healthcare sector will continue to be underfunded, making it difficult for the
country to achieve its healthcare-related millennium development goals. This poses questions regarding the
population's access to treatment of infectious and chronic diseases. While the planned implementation of
universal healthcare coverage in 2015 will increase access to healthcare services, therefore providing
drugmakers with increased revenue-earning opportunities, we believe a continued lack of skilled medical

$1,295.00
Hungary Pharmaceuticals and Healthcare Report Q1 2015

Hungary Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 19 2014

BMI View: We expect the decline in Hungary's pharmaceutical market to stabilise in 2015, although
a challenging operating environment and regulatory burden will weigh on market growth. Our country risk
team also sees potential headwinds to spending growth, namely Hungary's excessive government deficits
and a German economic slowdown that will reverberate throughout the Central and Eastern European
region. Pricing pressures and slow uptake of new medicines will continue to present near-term headwinds

$1,295.00
Italy Pharmaceuticals and Healthcare Report Q1 2015

Italy Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 19 2014

BMI View: SN pharmaceutical expenditure will decline in 2014 - creating revenue pressures for
drugmakers and pharmacies in Italy and increasing out-of-pocket costs for the population. The government
aimed to slash public healthcare costs by EUR900mn (USD1.2bn) in 2012 and EUR1.8bn (USD2.4bn) in
2013 and aims to continue to contain healthcare spending by EUR2.0bn (USD2.7bn) in 2014 and
EUR2.1bn (USD2.8bn) in 2015.
Headline Expenditure Projections
■ Pharmaceuticals: EUR20.91bn (USD27.60bn) in 2013 to EUR19.94bn (USD26.71bn) in 2014; -4.7% in

$1,295.00
Nigeria Pharmaceuticals and Healthcare Report Q1 2015

Nigeria Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 12 2014

BMI View: The Nigerian government remains committed to improving healthcare quality and
infrastructure across the country. The formation of the National Health Insurance Scheme (NHIS) has seen
a growing number of citizens enrolled since its formation in 2005, albeit lower than previously anticipated.
We believe Nigeria's pharmaceutical market has the capacity for considerable future growth in the long
term due to its increasing population and high burden of disease. Despite this, scant healthcare funding,

$1,295.00
Pakistan Pharmaceuticals and Healthcare Report Q1 2015

Pakistan Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 12 2014

BMI View: Pakistan holds great potential for pharmaceutical and healthcare companies, with the world's
sixth largest population. However, poor medical infrastructure, low per capita incomes and the high levels
of counterfeit medicines prevent the market from realising this potential. This leaves the majority of the
population without access to healthcare, save for Pakistan's elite class who can afford innovative
medicines.
Headline Expenditure Projections

$1,295.00
Sweden Pharmaceuticals and Healthcare Report Q1 2015

Sweden Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 12 2014

BMI View: Declining government reimbursement for prescription medicines does not bode well for
innovative drugmakers selling their products in Sweden, particularly as the government is the primary
purchaser of pharmaceuticals. Furthermore, over the long term, pushing costs onto a population with fewer
young people to financially support the elderly will ultimately work to reduce the consumption of highervalue
innovative pharmaceuticals.
Headline Expenditure Projections

$1,295.00
Australia Pharmaceuticals and Healthcare Report Q1 2015

Australia Pharmaceuticals and Healthcare Report Q1 2015

Date Published: Nov 12 2014

BMI View: The Australian government will continue to use drug price controls as a means to reduce
healthcare expenditure. Our view is based on the government's runaway budget deficit and the inevitable
increased demand for medicines as the population ages and incidence of long-term diseases rise.
Consequently, government price controls will continue to present downside risk to drugmakers selling their
products in Australia. The need to curb growing healthcare expenditure and high medicine prices will

$1,295.00

Pages

Shopping cart

0 Items $0.00
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianIntel, TPG, Elit Net, Cross Business Producers, AcmavolpakB. Braun, Cobham, fiserv, Harris, Wipro, AonAl Meera, Nomura Research Institute, Tata Consultancy Services, Amara Raja, Hiranandani EnergyMunich Re, Lotte Chemical, National Post, First Data